-
公开(公告)号:US20110082195A1
公开(公告)日:2011-04-07
申请号:US12863842
申请日:2009-01-21
IPC分类号: A61K31/352 , A61K31/045 , A61P3/04 , A61P3/10 , A61P3/00 , A61P9/00
CPC分类号: A61K31/352 , A61K31/05
摘要: The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease.
摘要翻译: 本发明涉及在制造用于控制受试者中的胆固醇水平的药物或中性制剂中单独使用或与另一种大麻素组合使用。 它还涉及在制造用于增加受试者的能量消耗的药物或中性制剂中单独或与另一种大麻素组合使用THCV。 此外,单独使用CBD或与另一种大麻素或单独使用THCV或与另一种大麻素组合的CBD被用作管理或治疗I型或II型糖尿病,肥胖,血脂异常,相关代谢紊乱和心血管疾病的制度的一部分。